Genzyme to Acquire GelTex Pharmaceuticals for $187 Million

Strategic Insights -

Genzyme Corp., a biotechnology company, has announced plans to acquire GelTex Pharmaceuticals, Inc. for $187 million in a deal that would bring GelTex's portfolio of non-absorbed polymer drugs and therapeutic products under Genzyme's umbrella. The acquisition is expected to close in December or January, pending regulatory and shareholder approval.

Genzyme's General division, which develops and markets therapeutic products, stands to gain significantly from the deal, with access to GelTex's patent-protected products, including Renagel and WelChol, as well as a promising pipeline of products and a team of experienced polymer technology developers. GelTex's flagship product, GT160-246, a toxin binder for Clostridium difficile, is in Phase 2 clinical trials, while its polymers that inhibit pancreatic lipase have shown promising results in pre-clinical studies.

Key Takeaways:

  • Genzyme Corp. plans to acquire GelTex Pharmaceuticals for $187 million, with the deal expected to close in December or January pending regulatory and shareholder approval.
  • The acquisition will bring GelTex's portfolio of non-absorbed polymer drugs and therapeutic products under Genzyme's umbrella, including market-approved Renagel and WelChol.
  • Genzyme's General division will gain access to GelTex's pipeline of products, including the Phase 2 clinical trial candidate GT160-246, a toxin binder for Clostridium difficile.
  • GelTex's polymer technology development team has produced two approved products and several promising candidates within a six-year timespan.
  • The acquisition will give Genzyme a head start in the development of non-absorbed polymer drugs and therapeutic products, with potential applications in the treatment of genetic disorders.
  • GelTex's management team will join Genzyme, bringing their experience in the development of non-absorbed polymer drugs and therapeutic products.

Statistics:

  • $187 million: The total value of the acquisition.
  • 2: The number of approved products developed by GelTex's polymer technology development team.
  • 6: The number of years it has taken GelTex to develop its pipeline of products.
  • 22%: The growth rate of Renagel, a rapidly growing product used in the treatment of patients with end-stage renal disease undergoing hemodialysis.

Sources:

  • Genzyme press release, November 1, 2000
  • GelTex press release, 2000
  • SEC filings (Genzyme and GelTex)